Murphy & Mullick Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$71.7K Buy
455
+290
+176% +$45.8K 0.04% 249
2026
Q2
$57.8K Hold
165
– – 0.04% 279
2026
Q1
$21.1K Hold
165
– – 0.02% 391
2025
Q4
$20.1K Hold
165
– – 0.01% 399
2025
Q3
$18.5K Hold
165
– – 0.01% 396
2025
Q2
$13.7K Hold
165
– – 0.01% 416
2025
Q1
$13.4K Hold
165
– – 0.01% 400
2024
Q4
$14.9K Hold
165
– – 0.01% 393

Other funds holding XBI

Murphy & Mullick Capital Management's XBI Position: Q3 2026 in Review

Murphy & Mullick Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 176% in Q3 2026, buying an estimated $45.8K and bringing the position to 455 shares worth $71.7K. The position accounts for 0.04% of the portfolio, ranked #249.

Murphy & Mullick Capital Management first reported a position in XBI in Q4 2024 and has held it in 8 quarters since. 962 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Murphy & Mullick Capital Management held 455 shares of State Street SPDR S&P Biotech ETF worth $71.7K as of Q3 2026.
  • Murphy & Mullick Capital Management bought 290 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $45.8K.
  • State Street SPDR S&P Biotech ETF made up 0.04% of Murphy & Mullick Capital Management's portfolio in Q3 2026, its #249 holding.
  • Murphy & Mullick Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 8 quarters since.
  • 962 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.